Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Merck
Dow
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TALIMOGENE LAHERPAREPVEC

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Talimogene laherparepvec

Trial ID Title Status Sponsor Phase Summary
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed Symbion Research International Phase 2 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT00289016 A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma Completed BioVex Limited Phase 2 The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated Amgen Phase 3 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
NCT01161498 Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer Terminated BioVex Limited Phase 3 This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Talimogene laherparepvec

Condition Name

Condition Name for
Intervention Trials
Melanoma 9
Breast Cancer 3
Unresected Stage IIIb to IVM1c Melanoma 3
Squamous Cell Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Melanoma 18
Carcinoma 6
Breast Neoplasms 4
Sarcoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Talimogene laherparepvec

Trials by Country

Trials by Country for
Location Trials
United States 129
Spain 16
Australia 10
United Kingdom 7
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Kentucky 10
Texas 9
New York 9
California 9
New Jersey 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Talimogene laherparepvec

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 6
Phase 2 15
Phase 1/Phase 2 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 17
Not yet recruiting 10
Active, not recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Talimogene laherparepvec

Sponsor Name

Sponsor Name for
Sponsor Trials
Amgen 24
Merck Sharp & Dohme Corp. 4
BioVex Limited 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 35
Other 24
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
Johnson and Johnson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.